Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

Tetra Bio-Pharma Expands Focus of Commercialization Activities into the Lucrative Veterinary Market $TPB.ca

Posted by AGORACOM-JC at 8:27 AM on Wednesday, June 28th, 2017

Tbp large

  • Commercializing novel cannabinoid based formulations for the treatment of pet conditions
  • Tetra will adopt a similar regulatory approach of transparency and collaboration with the veterinary drug authorities

OTTAWA, ONTARIO–(June 28, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today that it will also commercialize novel cannabinoid based formulations for the treatment of pet conditions.

Over the last year, Tetra demonstrated its leadership in the development of human prescription cannabinoid drugs and will use the same strategy to become a leader in the field of veterinary cannabinoid drug products. Tetra will adopt a similar regulatory approach of transparency and collaboration with the veterinary drug authorities. In fact, Tetra is well suited to tackle the veterinary drug market since the ACMPR was created to allow human patient’s access to medical marijuana and does not provide any measures to allow testing of cannabis or cannabis derived products in pets.

According to a USA Federal Trade Commission May 2015 report, in 2014, Americans spent approximately $58 billion on their pets, including medications. This number more than doubled since 2001. This market is expected to enjoy excellent growth over the next decade as new therapies provide better and more tolerable treatment for pets. According to Andre Rancourt, CEO of Tetra Bio-Pharma, “After carefully studying the veterinary pet market and potential partnerships, the company decided to expand its development activities in order to tap into this lucrative market. In addition, Tetra is very fortunate to have Dr. Chamberland who has considerable experience navigating the regulatory affairs in the veterinary industry.”

Tetra had announced the successful completion of several corporate milestones associated with the development of its prescription drug products. These announcements lead to discussions with veterinary specialists who expressed the need for novel cannabinoid therapies for pets.

Tetra will create a Veterinary Advisory board consisting of veterinary specialists in the fields of ophthalmology, oncology and pain. This board of veterinary experts will help guide the development to ensure that the products target unmet veterinary needs for domestic animals. Tetra will use the veterinary drug development program to expand its potential revenues from the sales of a drug product in both the human and pet drug markets. The corporation will also establish partnerships with pharmaceutical companies specialized in the sale and distribution of veterinary products.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Tetra Bio-Pharma Appoints Aphria CFO, Mr. Carl Merton to the Board of Directors $TBP.ca

Posted by AGORACOM-JC at 9:00 AM on Wednesday, June 14th, 2017

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564502/hub/TBP_large.jpg

  • Appointed Mr. Carl A. Merton to the Board of Directors, effective immediately. 

OTTAWA, ONTARIO–(June 14, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has appointed Mr. Carl A. Merton to the Board of Directors, effective immediately.

Mr. Merton has over 20 years of financial and business experience, including 10 years experience as a CFO for public companies involved in the capital markets. Beginning with 12 years combined with Ernst & Young and KPMG, he transitioned from the audit stream into financial advisory work, as a Business Valuator, Forensic Accountant and Corporate Finance functions. After leaving KPMG, Mr. Merton joined Atlas Tube Inc., as Vice-President, Special Projects. After assisting in the sale of Atlas Tube, Mr. Merton became the CFO of Reko International Group Inc. In December 2014, Mr. Merton was elected by shareholders as a member of the inaugural Board of Directors of Aphria Inc. Approximately one year later, Mr. Merton resigned as a member of the Board and joined Aphria as its CFO. In his role as CFO, Mr. Merton is responsible for communication with all stakeholders and is a member of the executive management team responsible for the strategic direction of Aphria, as well as leading all acquisition discussions, budgeting, financing, financial reporting and internal controls. Mr. Merton is a Chartered Professional Accountant, a Chartered Accountant and is a Fellow of the Canadian Institute of Chartered Business Valuators (the “CICBV”). He holds a B.Comm. Hon. in Sports Administration from Laurentian University, and has served as a past Chair of both the CICBV and the International Association of Professional Business Valuators. Mr. Merton is currently a member of the Board of Directors and Chair of the Audit Committee of Motor City Community Credit Union.

“We are most pleased to welcome Mr. Merton to the board as we continue to work closely with our strategic partner, Aphria in building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, Chairman and CEO of Tetra Bio-Pharma. “Mr. Merton’s tremendous experience as a CFO of publicly listed companies has resulted in raising in excess of $200 million. His vast network both in the U.S. and Canada will be a key factor in the Company’s growth. We look forward to working closely with him in building Tetra as a global leader in pharmaceutical cannabis.”

About Tetra Bio-Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(514) 360-8040 Ext. 20

Tetra Bio-Pharma Strengthens its Board with the Appointment of Dr. Bill Cheliak $TBP.ca

Posted by AGORACOM-JC at 4:13 PM on Tuesday, May 30th, 2017

Tbp large

  • Announced that it has appointed Dr. W.M. (Bill) Cheliak to the Board of Directors effective immediately
  • Dr. Cheliak is CEO of Panag Pharma, a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation
  • Over 20 years of experience as an entrepreneur having helped establish companies in a wide variety of life science fields, including vaccines, human genetics, oncology, neurology and anti-infective drug development and CRO services

OTTAWA, ONTARIO–(May 30, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has appointed Dr. W.M. (Bill) Cheliak to the Board of Directors effective immediately.

Dr. Cheliak is CEO of Panag Pharma, a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation. Dr. Cheliak has over 20 years of experience as an entrepreneur having helped establish companies in a wide variety of life science fields, including vaccines, human genetics, oncology, neurology and anti-infective drug development and CRO services. He brings extensive deal making experience with the pharmaceutical industry. He currently serves as a Director for Solarvest (SVS). Dr. Cheliak is Vice Chair of the Government of Canada’s Networks Centres Excellence (NCE) Standing Selection Committee and Chair of the NCE Monitoring Committee.

“We are most pleased to welcome Dr. Cheliak to the board as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, Chairman and CEO of Tetra Bio-Pharma. “As Tetra is now completely focused on becoming a global leader in pharmaceutical cannabis, Dr. Cheliak’s strong pharmaceutical background, knowledge and extensive networks will support the Company in the execution of its business plan.”

About Tetra Bio Pharma:

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(514) 360-8040 Ext. 203

Marijuana Company of America Announces the Filing of Form 10 Reg Statement with SEC + Apply for QB upgrade $MCOA.us

Posted by AGORACOM-JC at 11:16 AM on Tuesday, May 23rd, 2017

15233 mcoa

  • Filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission
  • Important step in helping the Company to raise the necessary capital to fund its projects and expand its operations, as well as provide more transparent and reliable information to investors
  • Company will apply to upgrade its trading tier with OTC Markets to the OTCQB

BONSALL, CA–(May 23, 2017) – MARIJUANA COMPANY OF AMERICA, INC (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp company, is pleased to announce that it has filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). This is an important step in helping the Company to raise the necessary capital to fund its projects and expand its operations, as well as provide more transparent and reliable information to investors.

Once the registration statement becomes effective, the Company will apply to upgrade its trading tier with OTC Markets to the OTCQB. Upgrading to the OTCQB is an efficient way to raise the Company’s profile among the investor and broker dealer communities, access greater liquidity, and trade on an SEC-recognized market, removing many of the trading restrictions placed on Pink market securities. The Form 10 filing provides investors detailed and audited information about MCOA‘s operations, including an overview of the business strategies, risk factors and financial statements. This additional and reliable information will help our investors make a more educated investment decisions about the Company.

“Taking steps to become a fully reporting company is yet another way that we are distinguishing ourselves from most of the marijuana public companies that report under the Alternative Reporting Standards on the OTC Pink market,” said Donald Steinberg, CEO of MCOA. “MCOA experienced substantial growth in 2016 and we hope to continue this momentum throughout 2017 as well. Our Form 10 filing and ongoing SEC reporting disclosures through audited annual financial statements, auditor reviewed quarterly financial statements and all material events will provide additional transparency to our shareholders and the investment community on our performance as we grow.”

MCOA‘s Form 10 Registration Statement includes audited financial statements of the business, an overview of the markets and industries in which the Company will operate, details regarding the Company’s management, and competitive strengths, strategies and risk factors. A copy of the Form 10 is available at www.sec.gov under the name of Marijuana Company of America, Inc. Additionally, the Form 10 can be found on the Investors Relations portion of the Company’s website at www.marijuanacompanyofamerica.com

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Marijuana Company of America, Inc Announces the Launch of New Website $MCOA.us

Posted by AGORACOM-JC at 8:52 AM on Thursday, May 18th, 2017

15233 mcoa

  • Launched its new corporate website; www.marijuanacompanyofamerica.com.
  • Provides shareholders and prospective investors with helpful information to make educated investment decisions. As the Company continues to execute its strategic plans

BONSALL, CA–(May 18, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or “the Company”) (OTC PINK: MCOA), an innovative cannabis and industrial hemp corporation, is pleased to announce the launch of its new corporate website; www.marijuanacompanyofamerica.com.

The new website will provide our shareholders and prospective investors with helpful information to make educated investment decisions. As the Company continues to execute its strategic plans, this new site will be the central hub for information about MCOA and the rapidly emerging cannabis and hemp industry.

Since starting the process to become fully reporting and uplisting to a higher financial exchange, the OTCQB, the Company has been engaging with institutional investors and analyzing meaningful M&A opportunities in the cannabis and industrial hemp marketplaces. This new site will be a useful tool in providing investors with updates on these developments.

MCOA recently engaged Hill and DraKoln Media (“H&D”) to develop the new website and provide marketing and brand management support. MCOA looks forward to capitalizing on H&D’s ability to communicate clearly and concisely with investors and consumers alike. They will develop a strong and lasting presence for the Company’s brands. MCOA will take full advantage of H&D’s ability to reach audiences across a variety of demographics related to our industry and expand our reach into new territory.

“We are very happy to finally be launching our new corporate website. David Hill and the Hill & DraKoln group did a wonderful job on the new site and we look forward to them launching the comprehensive branding and marketing strategy they are developing for the Company,” said Mr. Steinberg, MCOA President & CEO.

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Contact:
Marijuana Company of America, Inc
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Tetra Bio-Pharma Files Patent for the Treatment of Cancer and Ocular Disease $TBP.ca

Posted by AGORACOM-JC at 4:17 PM on Wednesday, May 17th, 2017

Tbp large

  • Submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease
  • Global market for cancer drugs has hit US$100 billion in annual sales
  • Could reach US$147 billion by 2018, according to a new report by IMS Institute for Healthcare Informatics

OTTAWA, ONTARIO–(May 17, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:GRPOF), today announced that Tetra has submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease.

The global market for cancer drugs has hit US$100 billion in annual sales, and could reach US$147 billion by 2018, according to a new report by the IMS Institute for Healthcare Informatics. According to Transparency Market Research, the global ophthalmic drug market is expected to reach US$21.6 billion by 2018 due to high incidence of eye-related disorders amongst geriatrics. The provisional patent aims to protect new pharmaceutical combinations of cannabinoids and terpenoids to inhibit a specific signaling pathway, known as Hedgehog (Hh), and their use to combat human diseases.

“Filing of this provisional patent marks the launch of an innovative and exciting project that could not only impact patients suffering from a variety of human diseases, but also further Tetra’s interests in developing and commercializing novel cannabinoid-based pharmaceutical drugs,” said Dr. Guy Chamberland, Chief Scientific Officer of Tetra. “The rationale forming the basis for this project is well founded and our research team has extensive scientific experience in the Hh field. We look forward to quickly advancing the project through key academic collaborations, with the ultimate goal of developing multiple pharmaceutical treatments.”

Background Information:

Hh signaling is a critical developmental molecular signaling pathway and inappropriate over activation of Hh is causal in several types of human tumors, including medulloblastoma, basal cell carcinoma, rhabdomyosarcoma, and multiple forms of leukemia, as well as liver, stomach, small cell lung, prostate, and breast cancers. Hh signaling also regulates the formation and remodeling of blood vessels, and aberrant blood vessel growth is implicated in several human diseases. The eye is particularly vulnerable to dysfunctional angiogenesis and neovascularization, such as in the case of diabetic retinopathy, age-related macular degeneration, neovascular glaucoma, retinal vein occlusion and retinopathy of prematurity, where inappropriate ocular blood vessel growth often leads to irreversible blindness if left untreated.

Currently, there are few clinically approved treatments for Hh-pathway-dependent cancers and drug resistance remains a major hurdle. As well, current treatment approaches to neovascular and angiogenic ocular disease are insufficiently effective and have significant adverse effects. Thus, there is a large need to develop novel therapies to treat human cancers and ocular disease related to blood vessel growth. Recently, cannabinoids have emerged as novel and potent inhibitors of the Hh signaling pathway and terpenoids have been shown to modulate the effects of cannabinoids through an undefined mechanism. Tetra looks to capitalize on these recent findings by filing a provisional patent for the use of cannabinoids in combination with terpenoids to treat Hh related cancer growth and aberrant blood vessel growth in the eye. Securing a provisional patent and achieving the freedom to operate is an important first step in the realization of this project.

About Tetra-Bio Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Namaste Signs Agreement With Peeks Social to Promote and Sell Vaporizers in Peeks Platform $N.ca

Posted by AGORACOM-JC at 9:12 AM on Wednesday, May 17th, 2017

Nlogo

  • Signed a marketing agreement with Peeks Social Ltd. (“Peeks”) (TSX VENTURE:PEEK)(OTCQB:KEEKF)
  • To promote Namaste’s product offering as a preferred vendor on its iOS and Android Apps
  • Namaste and Peeks will work with strong social influencers actively involved in the network and supportive of the medical cannabis industry to promote certain brands of products selected by Namaste

VANCOUVER, BRITISH COLUMBIA–(May 17, 2017) –

Namaste Technologies Inc. (“Namaste” or the “Company“) (CSE:N)(CSE:N.CN)(CNSX:N)(FRANKFURT:M5BQ)(OTCQB:NXTTF) is pleased to announce that it has signed a marketing agreement (the “Agreement“) with Peeks Social Ltd. (“Peeks“) (TSX VENTURE:PEEK)(OTCQB:KEEKF) in order to promote Namaste’s product offering as a preferred vendor on its iOS and Android Apps. Namaste and Peeks will work with strong social influencers actively involved in the network and supportive of the medical cannabis industry to promote certain brands of products selected by Namaste. Namaste products will be promoted through these influencers and available for sale on Peeks’ platform. Peeks is a high growth social media platform that appeals to Namaste’s target demographic of consumers.

Agreement Terms

  • Peeks will provide a marketing & sales program through multiple social influencers on Peeks
  • Peeks will include Namaste within featured categories on Peeks
  • Namaste will provide samples to high traffic social influencers in the Peeks platform
  • Namaste will participate in Peeks Offer Box Program
  • Namaste will set up and operate its own Peeks channels
  • Namaste will share the Peeks platform through Namaste’s social media channels
  • Namaste will add the Peeks logo to its website (with call-to-action)
  • Namaste will set up intro videos on the main Namaste Peeks channels

About Peeks

Peeks is a publicly traded company listed on the TSX Venture Exchange under the symbol “PEEK” and on the OTCQB under the symbol “KEEKF”. Its principal activity is the development of social media and social commerce products and services for use by consumers and businesses, with a focus on mobile (iOS and Android) products. The Peeks head office is located at 184 Front Street East, Suite 701, Toronto, Canada, M5A 4N3.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We are very happy to have signed this agreement with Peeks Social. We have seen an overwhelming response from strong social influencers in the platform that are wanting to get involved with promoting Namaste products. We are working closely with the Peeks management and operations team to build out the Namaste channel and scheduling for promotional videos in the platform.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors,

Sean Dollinger, Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
info@namastevapes.com

Tetra Bio-Pharma Strengthens Management Team $TBP.ca

Posted by AGORACOM-JC at 4:34 PM on Wednesday, May 10th, 2017

Tbp large

  • Appointment of Robert Bechard to the position of Vice President, Finance and Business Development
  • Brings more than 20 years’ experience in the biopharmaceutical industry having worked for two lifescience venture capital funds, a pharmaceutical R&D management firm, a drug delivery company, and as a consultant to the biotech industry

OTTAWA, ONTARIO–(May 10, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF), today announced that it has strengthened its management team with the appointment of Robert Bechard to the position of Vice President, Finance and Business Development, effective today, May 10, 2017.

Mr. Bechard brings more than 20 years’ experience in the biopharmaceutical industry having worked for two lifescience venture capital funds, a pharmaceutical R&D management firm, a drug delivery company, and as a consultant to the biotech industry. As Vice President of Finance and Business Development, Mr. Bechard will be responsible for leading the charge on business development as it relates to the pharmaceutical side of the business and managing the financial side of the company.

During his tenure at RBC Lifesciences Funds I&II, Mr. Bechard was a member of the Senior Management team that delivered top quartile returns in two separate funds. RBC Lifesciences. During his 12-year term as a venture capitalist Mr. Bechard, made numerous investments, sat on the boards of more than 25 life science companies and was actively involved in the negotiation of numerous strategic alliances, partnerships, and outright sales to both pharmaceutical and biotech companies. As a Board member he played an active role in the negotiation of numerous exits and was also actively involved in taking several companies public in Canada and the U.S. In his two operating roles, he was instrumental in contributing to the growth of two companies actively involved in developing pharmaceuticals. As a consultant to the biopharmaceutical industry Mr. Bechard provided start-up companies with assistance in the areas of fundraising, business development and corporate development.

“We are most pleased to welcome Bob to the team as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “Mr. Bechard has built great relations over his career in the pharmaceutical industry which will open new opportunities to further expand our product pipeline through partnerships as we build Tetra into a global leader in pharmaceutical cannabis.”

About Tetra Bio Pharma:

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE: TBP) (OTCQB: GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(343) 689-0714
edward@tetrabiopharma.com

Marijuana Company of America Invests in Global Payout’s MoneyTrac $MCOA.us

Posted by AGORACOM-JC at 9:09 AM on Wednesday, May 3rd, 2017

15233 mcoa

  • Announced an investment of $250,000 in exchange for 15% of MoneyTrac Technology, Inc.
  • Subsidiary of Global Payout (OTC: GOHE)
  • Investment will serve as an excellent resource for MTT in their current objective of establishing the MoneyTrac Technology payment platform

BONSALL, CA–(May 3, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce an investment of $250,000 in exchange for 15% of MoneyTrac Technology, Inc. (“MTT”), a subsidiary of Global Payout (OTC: GOHE).

This investment will serve as an excellent resource for MTT in their current objective of establishing the MoneyTrac Technology payment platform as a major competitor within the alternative banking sector, and more specifically be leveraged in their efforts to extend their marketing campaign to cannabis-related companies who are at the core of MTT’s target market.

In addition to this investment from MCOA, MTT is also pleased to announce that its Board of Directors (“the Board”) has approved the appointment of MCOA CEO, Don Steinberg as a board member with the intention of diversifying their Board through his invaluable experience and knowledge in the early-stage development of companies, and overseeing MCOA shareholder’s investment into MTT.

In addition to his current role at MCOA as founder, CEO and director, Mr. Steinberg was also the founder of Medical Marijuana Inc., the first publicly traded marijuana company in 2009.

“We are pleased and appreciative of the confidence and enthusiasm MCOA has demonstrated with this investment, and we are committed to leveraging it in the most effective manner possible in this all-important stage of our development,” said MTT CEO, James Hancock. “We are also thrilled to welcome Mr. Steinberg to our Board as his experience extends to every corner of business development and operations, from company offerings, product and service management, and to the implementation of strategic marketing campaigns. I have had the distinct pleasure of working with him on several projects over the last decade and look forward to the expertise and energy he will bring to our Board,” Mr. Hancock further remarked.

“I am honored to be given the opportunity to join Mr. Hancock and Ms. Vanessa Luna on the MoneyTrac Board. The electronic payment and compliance features available through the MTT technology platform are the solutions many sectors of our Cannabis industry have been looking for, and I look forward to providing the MTT Board with guidance and support to help move their objectives forward in the most effective way possible,” said Mr. Steinberg.

About Marijuana Company of America (MCOA)
Marijuana Company of America (“MCOA”) is a publicly traded company headquartered in Southern California. MCOA will distribute marijuana and products related to marijuana as well as CBD and hemp, using a variety of marketing approaches to distribute on a global basis.

ABOUT MONEYTRAC, INC.
MoneyTrac Technology, Inc. (www.moneytractechnology.com) is a pioneer in offering a full-service solution for alternative banking and electronic financial solutions and provides all aspects of financial technology including E-Wallet and mobile apps services for businesses and companies in various “high-risk” industries. MoneyTrac’s technology platform allows for its clients to access their financial information from anywhere in the world, in addition to providing tracking and compliance to help them manage and control the flow of all revenue through their business.

ABOUT GLOBAL PAYOUT
Since the Company’s inception in 2009, Global Payout, Inc. (www.globalpayout.com) has been a leading provider of comprehensive and customized prepaid payment solutions for domestic and international organizations distributing money worldwide. In 2014, Global introduced its first online payment platform called the Consolidated Payment Gateway (CPG), which allowed its enterprise clients to transfer money to international bank accounts, mobile accounts, and prepaid card accounts. The development of the CPG became the foundation for the introduction of its new, state of the art FINTECH payment system in 2017, for both online and mobile applications to allow account holders to maximize an expanded suite of financial services and minimize operational costs. Global will continue to offer their FINTECH payment system to many vertical markets for support of foreign currency exchange and digital currency, including ongoing support of the banking industry and international governments.

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Contact:
Marijuana Company of America, Inc.
IR@mcoa.club

Namaste Announces DTC Eligibility $N.ca

Posted by AGORACOM-JC at 8:13 AM on Tuesday, April 25th, 2017

Nlogo

  • Secured DTC Eligibility by The Depository Trust Company for its shares on the OTCQB Venture Market effective April 21, 2017

VANCOUVER, BRITISH COLUMBIA–(April 25, 2017) – Namaste Technologies Inc. (“Namaste” or the “Company“) (CSE:N)(CSE:N.CN)(FRANKFURT:M5BQ)(OTCQB:NXTTF) is pleased to announce that it has secured DTC Eligibility by The Depository Trust Company (“DTC“) for its shares on the OTCQB Venture Market (“OTCQB“) effective April 21, 2017. DTC is a subsidiary of The Depository Trust & Clearing Corporation DTCC, and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors trading the Company’s shares on the OTCQB.

Management Commentary

Mr. Sean Dollinger, President and CEO of Namaste, comments: “We are very pleased to have obtained DTC eligibility. This will greatly simplify the process of trading and exchanging our stock in the United States. In the last year, we have developed significant US commercial operations and view being able to trade on the OTCQB as an important aspect of developing a following with US investors. With DTC eligibility, it will be much easier for investors to be part of our growing Company.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 e-commerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market, and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
info@namastevapes.com